Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
The development of novel HIV-1 vaccines using modified recombinant BCG
Vaccination continues to represent the most effective means of providing immunological protection against infectious disease in human populations. With the World Health Organisation (WHO) reporting over 1.2 million AIDS related deaths in 2014, an efficacious HIV1 vaccine is urgently needed. The UCT...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
Division of Virology
2017
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: The development of novel HIV-1 vaccines using modified recombinant BCG
- Recombinant BCG expressing HIV-1 C GAG : selection of the vaccine gene and construction and evaluation as a vaccine candidate
- Recombinant BCG expressing rotavirus VP6 : construction and evaluation as an anti-rotavirus vaccine
- Investigation of the use of recombinant BCG, expressing the major capsid protein (LI) of human papillomavirus type 16, as a candidate vaccine for cervical cancer
- Construction, stability and immunogenicity of recombinant BCG expressing HIV-1 subtype C gag under the control of MtrA promoter, with or without the leader sequences
- Evaluation of a reverse tetracycline inducible system in recombinant BCG to improve stability and immunogenicity
- Pre-clinical assessment of novel candidate HIV-1 vaccines using the Chacma baboon